Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parathyroid hormone as a therapeutic agent.

Bruce H Mitlak1

  • 1Medical Advisor, Eli Lilly and Company Lilly Corporate Center, Indianapolis, IN 46285, USA. b.mitlak@lilly.com

Current Opinion in Pharmacology
|December 17, 2002
PubMed
Summary

Parathyroid hormone therapy shows promise in reducing fracture risk in women and men. Research also examines its effects on bone structure and reviews potential risks like osteosarcoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of abaloparatide on the proximal femur in men with osteoporosis assessed by three-dimensional dual-energy X-ray absorptiometry.

JBMR plus·2025
Same author

Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture.

Menopause (New York, N.Y.)·2025
Same author

Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2024
Same author

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2021

Area of Science:

  • Endocrinology and Bone Metabolism
  • Pharmacology
  • Toxicology

Background:

  • Parathyroid hormone (PTH) is increasingly recognized for its therapeutic potential in bone health.
  • Osteoporosis treatment requires agents that not only increase bone density but also improve bone quality.

Purpose of the Study:

  • To summarize recent clinical advancements in parathyroid hormone therapy.
  • To evaluate the impact of PTH on fracture risk and bone microarchitecture.
  • To review safety data regarding long-term PTH administration.

Main Methods:

  • Controlled clinical trials assessing fracture reduction in postmenopausal women.
  • Clinical studies evaluating PTH efficacy and safety in men.
  • Bone histomorphometry and imaging techniques to analyze cortical and trabecular bone structure.
  • Review of long-term toxicology studies in animal models.

Main Results:

  • Evidence from controlled trials demonstrates PTH's effectiveness in reducing vertebral and non-vertebral fractures in women.
  • Studies in men indicate similar therapeutic benefits for bone health.
  • Assessment of bone structure reveals PTH's positive effects on both cortical and trabecular bone.
  • Toxicology studies provide insights into the safety profile of long-term PTH use.

Conclusions:

  • Parathyroid hormone represents a significant therapeutic advance for managing bone diseases, particularly osteoporosis.
  • PTH treatment positively influences bone structure, contributing to fracture risk reduction.
  • Ongoing safety evaluations, including reviews of toxicology data, are crucial for comprehensive risk-benefit assessment.

Related Experiment Videos